Weill Cornell/Rockefeller/Sloan-Kettering MST Program

描述(由申请人提供)：三院校医学博士项目是威尔康奈尔医学院(WCMC)、洛克菲勒大学(RU)和斯隆-凯特琳癌症研究所(SKI)的联合项目。它的使命是培养生物医学研究人员，一方面对生物医学科学有深入的了解，掌握现代研究技能，使他们能够进行基础研究，阐明与人类疾病有关的基本生物学过程；另一方面，他们在人类生物学、病理生物学和临床医学方面有很好的基础，这将使他们能够将基础研究的进展转化为对人类疾病的理解、预防和治疗。这三个机构经营着三个研究生院：威尔康奈尔医学研究生院(WCGS)，WCMC和SKI的联合项目；RU的大卫·洛克菲勒研究生院；以及SKI的Gerstner生物医学研究生院(GSK)。三机构MD-PhD计划成立于1991年，当时两个独立的MD-PhD计划--WCMC-RU计划和WCMC-WCGS计划--合并成了现在的计划。GSK于2009年成为该计划的一部分。MSTP学员完成WMC医学硕士学位的所有要求。他们将在这三个研究机构的研究实验室接受博士培训，并从GSK、RU或WCGS获得博士学位。被录取的实习生将在7月初医学院开学前抵达。在该计划的头两年，他们完成了医学院的课程，参加了为医学博士学生设计的两门研究生水平的课程，并完成了三次研究轮换(在三个不同的实验室)，然后他们进入了论文实验室。当TE学生选择一个研究实验室时，他们就进入了与他们的论文导师相关的研究生院。所有医学博士研究生的研究生课程和论文要求都是相同的，无论他们是在哪所研究生院注册的--学生可以交叉注册并在任何研究生院选修课程以获得学分。在他们的研究训练结束后，在他们为他们的论文辩护之后，学生们回来完成他们在WMC的临床训练。本申请书要求提供资金，以便在40年后继续在这三个机构进行医学博士培训(其前身WCMC-RU方案成立于1972年，1974年获得美国国立卫生研究院的资助)。在目前的迭代中，该计划将270多个独立研究实验室的教师聚集在一起。已有317名医学博士毕业于三所学院及其前身的医学博士项目；目前该项目有108名学生。目前的学员来自54所本科学校。他们的平均GPA为3.75，MCAT综合得分为35.1。94%的毕业生接受研究生临床培训；在完成培训的231名毕业生中，202名(87%)受聘于医学院、研究机构或生物技术/制药公司。

DESCRIPTION (provided by applicant): The Tri-Institutional MD-PhD Program is a joint undertaking of Weill Cornell Medical College (WCMC), The Rockefeller University (RU), and the Sloan-Kettering Institute for Cancer Research (SKI). Its mission is to train biomedical investigators who: on the one hand, have advanced understanding of biomedical science and a mastery of contemporary research skills, which will allow them to undertake fundamental studies to elucidate basic biological processes pertaining to human disease; and, on the other hand, are well grounded in human biology, pathobiology and clinical medicine, which will equip them to transfer advances in basic research to the understanding, prevention, and treatment of human disease. The three institutions operate three graduate schools: Weill Cornell Graduate School of Medical Sciences (WCGS), a joint undertaking between WCMC and SKI; the David Rockefeller Graduate School at RU; and the Gerstner Graduate School of Biomedical Sciences (GSK) at SKI. The Tri-Institutional MD-PhD Program was formed in 1991, when two independent MD-PhD Programs, the WCMC-RU Program and the WCMC-WCGS Program, were joined to form the present program. GSK became part of the Program in 2009. MSTP trainees complete all the requirements for the MD degree at WMC. They will get their PhD training in research laboratories in the three research institutions and receive their PhD degree from GSK, RU or WCGS. Accepted trainees arrive in early July before the start of medical school. During the first two years in the Program they complete their medical school course, take two graduate level courses designed for MD-PhD students, and complete three research rotations (in three different laboratories) before they settle into their thesis laboratory. When te students choose a research laboratory they enroll in the graduate school with which their thesis mentor is associated. The graduate course and thesis requirements are comparable for all MD-PhD students, irrespective of the graduate school in which they are matriculated-and the students can cross register and take courses for credit in any of the graduate schools. At the end of their research training, after they have defended their thesis, the students return to complete their clinical training at WMC. The present application requests funds to continue MD-PhD training at the three institutions beyond Year 40 (the predecessor WCMC-RU Program was formed in 1972; it received NIH funding in 1974). In its current iteration, the Program brings together faculty in more than 270 independent research laboratories. 317 MD- PhDs have graduated from the Tri-Institutional MD-PhD Program and its predecessors; currently there are 108 students in the Program. The current trainees come from 54 undergraduate schools. Their average GPA is 3.75, the combined MCAT score is 35.1. 94% of the graduates pursue post-graduate clinical training; of the 231 graduates who have completed their training, 202 (87%) have appointments in medical schools, research institutes or biotech/pharma.